Antibody-Drug Conjugates for the Treatment of Non-Small Cell Lung Cancer with Central Nervous System Metastases
David J H Bian1, Sara F Cohen2, Anna-Maria Lazaratos3,4
1Department of Internal Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3A 1G1, Canada.
Abstract:
Antibody-drug conjugates (ADCs) represent an emerging class of targeted anticancer agents that have demonstrated impressive efficacy in numerous cancer types. In non-small cell lung cancer (NSCLC), ADCs have become a component of the treatment armamentarium for a subset of patients with metastatic disease. Emerging data suggest that some ADCs exhibit impressive activity even in central nervous system (CNS) metastases, a disease site that is difficult to treat and associated with poor prognosis. Herein, we describe and summarize the existing evidence surrounding ADCs in NSCLC with a focus on CNS activity.
Insights
Antibody-drug conjugates (ADCs) show promise in treating non-small cell lung cancer (NSCLC), including difficult-to-treat brain metastases. These targeted therapies offer new hope for patients with advanced NSCLC and central nervous system involvement.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Background:
- Antibody-drug conjugates (ADCs) are a novel class of targeted anticancer therapies.
- ADCs have shown significant efficacy across various cancer types.
- In non-small cell lung cancer (NSCLC), ADCs are increasingly used for metastatic disease.
Purpose of the Study:
- To review and summarize current evidence on ADCs in NSCLC.
- To specifically focus on the activity of ADCs in central nervous system (CNS) metastases.
- To highlight the potential of ADCs in a challenging area of NSCLC treatment.
Main Methods:
- Literature review of existing studies on ADCs in NSCLC.
- Analysis of data focusing on efficacy in CNS metastases.
- Synthesis of evidence regarding treatment outcomes and challenges.
Main Results:
- ADCs have demonstrated notable efficacy in treating metastatic NSCLC.
- Emerging data indicate promising activity of certain ADCs against CNS metastases.
- CNS metastases in NSCLC are historically difficult to treat with poor prognosis.
Conclusions:
- ADCs represent a valuable therapeutic option for a subset of NSCLC patients.
- The efficacy of ADCs in CNS metastases warrants further investigation.
- ADCs may offer a new treatment avenue for NSCLC patients with brain involvement.
